Drug Profile
Mepivacaine controlled release - Heron Therapeutics
Alternative Names: APF112Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator A.P. Pharma
- Developer Heron Therapeutics
- Class Local anaesthetics; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Postoperative pain
Most Recent Events
- 13 Jan 2014 A.P. Pharma is now called Heron Therapeutics
- 27 May 2008 Phase II development is ongoing
- 12 Dec 2006 Mepivacaine controlled release is still available for partnering (http://www.appharma.com)